Equities research analysts expect that Antares Pharma Inc (NASDAQ:ATRS) will report $26.36 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Antares Pharma’s earnings, with the highest sales estimate coming in at $27.30 million and the lowest estimate coming in at $24.60 million. Antares Pharma posted sales of $17.87 million in the same quarter last year, which suggests a positive year-over-year growth rate of 47.5%. The business is expected to issue its next quarterly earnings results on Tuesday, November 5th.

On average, analysts expect that Antares Pharma will report full-year sales of $108.05 million for the current fiscal year, with estimates ranging from $106.20 million to $109.20 million. For the next year, analysts anticipate that the firm will post sales of $155.99 million, with estimates ranging from $140.70 million to $165.47 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. The firm had revenue of $28.43 million during the quarter, compared to analyst estimates of $21.66 million. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%.

Separately, BidaskClub downgraded Antares Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, August 20th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $5.04.

Shares of NASDAQ:ATRS traded up $0.12 during trading on Monday, reaching $3.48. 902,768 shares of the company traded hands, compared to its average volume of 1,006,463. The company has a current ratio of 3.46, a quick ratio of 2.87 and a debt-to-equity ratio of 1.01. The firm has a market capitalization of $567.46 million, a price-to-earnings ratio of -87.00 and a beta of 0.90. The business’s fifty day moving average is $3.23 and its 200-day moving average is $3.11. Antares Pharma has a 52-week low of $2.53 and a 52-week high of $3.96.

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its holdings in shares of Antares Pharma by 54,541.8% during the first quarter. BNP Paribas Arbitrage SA now owns 30,053 shares of the specialty pharmaceutical company’s stock valued at $91,000 after acquiring an additional 29,998 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Antares Pharma during the first quarter valued at approximately $123,000. Fosun International Ltd raised its holdings in shares of Antares Pharma by 36.8% during the second quarter. Fosun International Ltd now owns 809,378 shares of the specialty pharmaceutical company’s stock valued at $2,574,000 after acquiring an additional 217,670 shares in the last quarter. AE Wealth Management LLC bought a new position in shares of Antares Pharma during the second quarter valued at approximately $98,000. Finally, Bank of America Corp DE raised its holdings in shares of Antares Pharma by 112.6% during the fourth quarter. Bank of America Corp DE now owns 101,544 shares of the specialty pharmaceutical company’s stock valued at $276,000 after acquiring an additional 53,772 shares in the last quarter. Institutional investors own 38.76% of the company’s stock.

About Antares Pharma

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Featured Article: How to Invest in a Bull Market

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.